TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $5.63 million versus the consensus estimate of $5.33 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.